Drugs / XW001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05779995 | Apr → Oct 2023 | respiratory syncytial virus infectious disease | Hangzhou Sciwind Biosciences Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05083117 | Oct 2021 → Mar 2022 | acute respiratory distress syndrome | Sciwind Biosciences APAC CO Pty. Ltd. | Withdrawn | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05642403 Comparator | Jan 2021 → Jun 2022 | respiratory syncytial virus infectious disease | Hangzhou Sciwind Biosciences Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XW001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05642403 ↗ |
| Route | Inhaled | “Treatment arm patients will receive inhaled XW001 1 mg” NCT05083117 ↗ |